



Stuart M. Falber

PARTNER
Co-Chair, Life Sciences Group

BOSTON
+ 1 617 526 6663
STUART.FALBER@WILMERHALE.COM

Stuart Falber represents clients in the life sciences area. For nearly 30 years, Mr. Falber has served as counsel for a broad range of life sciences clients, ranging from startup private companies to mature public companies, investment banks and venture capital funds.

Mr. Falber's practice focuses on corporate and securities law, with an emphasis on private and public company counseling; representation of issuers, investment banks and investors in venture capital transactions, public offerings and other financing transactions; mergers and acquisitions, including public and private company acquisitions and dispositions, asset acquisitions and sales, and public and private company spinoffs; and corporate collaborations and licensing transactions.

Learn more about Mr. Falber's practice and how he can support your startup on WilmerHaleLaunch.com.

Professional Activities

Mr. Falber is a member of the American Bar Association, the Massachusetts Bar Association and the Boston Bar Association, as well as the Boston Bar Association's 2017 Life Sciences Conference Advisory Committee.

Solutions

Capital Markets

Emerging Company and
Venture Capital

Corporate Governance and
Disclosure

Life Sciences

Cross-Border Transactions

Mergers and Acquisitions

Experience

- **VENTURE CAPITAL TRANSACTIONS**
 - Accent Therapeutics, Inc. in its \$40 million Series A financing round
 - Apellis Pharmaceuticals, Inc. in its \$60 million Series E financing round
 - Disarm Therapeutics, Inc. in its \$30 million Series A financing round
 - Generation Bio Co. in its \$100 million Series B financing round
 - Trevi Therapeutics, Inc. in its \$50 million Series C financing round
- **PUBLIC OFFERINGS**
 - Aileron Therapeutics, Inc., in its initial public offering in July 2017
 - Apellis Pharmaceuticals, Inc. in its \$150 million initial public offering in November 2017, its \$140 million follow-on offering in April 2018 and its \$117 million underwritten public offering in March 2019
 - Epizyme in multiple follow-on public offerings, including its \$86.25 million public offering in October 2018
 - Idera Pharmaceuticals, Inc. in multiple follow-on public offerings, including its \$57.5 million public offering in October 2017
 - Tetrphase Pharmaceuticals, Inc. in its \$80.5 million initial public offering and in multiple follow-on public offerings, including its most recent \$65.7 million public offering in August 2017
 - Tokai Pharmaceuticals in its \$105.3 million initial public offering
- **MERGER AND ACQUISITION TRANSACTIONS**
 - Braintree Laboratories in its sale to Sebelo Pharmaceuticals
 - Investors Abingworth Bioventures and Atlas Venture in the sale of IFM Therapeutics to Bristol-Myers Squibb
 - Tokai Pharmaceuticals Inc. in a share purchase agreement with Otic Pharma Ltd.
 - The Medicines Company in its acquisition of Incline Therapeutics for up to \$390 million, including contingent payments
 - Penwest Pharmaceuticals Co. in its sale to Endo Pharmaceuticals, Inc. for \$144 million
 - Gloucester Pharmaceuticals, Inc. in its sale to Celgene, Inc. for up to \$640 million, including contingent payments
 - Transkaryotic Therapies, Inc. in its sale to Shire Pharmaceuticals Group plc for \$16 billion
- **PIPE AND 144A TRANSACTIONS**
 - The Medicines Company in 144A convertible note offerings, including its \$350 million offering in January 2015
 - Argos Therapeutics, Inc. in multiple PIPE transactions, including its \$60 million

- PIPE transaction
- Spring Bank Pharmaceuticals, Inc. in its \$15 million PIPE transaction
- Idera Pharmaceuticals, Inc. in PIPE transactions raising a total of \$17 million
- New Leaf Ventures in a PIPE transaction by MEI Pharma, Inc. raising a total of \$27.5 million
- **CORPORATE COLLABORATIONS AND LICENSING TRANSACTIONS**
- Apellis Pharmaceuticals, Inc. in a risk-sharing collaboration with SFJ Pharmaceuticals
- ZIOPHARM Oncology, Inc., Braintree Laboratories, Inc. and Idera Pharmaceuticals, Inc. in various licensing transactions

Recognition

- Recognized as a Life Sciences Star in 2018 by *LMG Life Sciences*
- Named one of the 2017-2019 *Best Lawyers in America* in the areas of biotechnology law and corporate law
- Recommended in the 2016-2018 editions of *The Legal 500 United States* for healthcare; life sciences and capital markets: equity offerings
- Recognized as a leading lawyer in the 2018 *Life Sciences Expert Guide*

Credentials

EDUCATION

JD, University of Pennsylvania
Law School

magna cum laude

*Order of the Coif; Senior Editor,
University of Pennsylvania Law
Review*

BA, Tufts University

cum laude

ADMISSIONS

Massachusetts